Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

Chronic metabolic acidosis (CMA) in normal adults results in complex endocrine and metabolic alterations including growth hormone (GH) insensitivity, hypothyroidism, hyperglucocorticoidism, hypoalbuminaemia and loss of protein stores.

Similar alterations occur in chronic renal failure, a prototypical state of CMA.

Who Took Part

According to the abstract, 14 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

What Was Measured

The researchers evaluated whether metabolic acidosis contributes to the endocrine and metabolic alterations characteristic of end-stage renal disease.

Topics PubMed links to this paper include Acidosis, Bicarbonates, Blood Gas Analysis, Citrates, Cytokines, Human Growth Hormone and Renal Dialysis.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.